Cyclin E2及Survivin在急性白血病表达及其相关性.docVIP

Cyclin E2及Survivin在急性白血病表达及其相关性 　 ; 作者：王颖，徐世荣，林凤茹，郭晓楠，任金海; 毕业论文 【摘要】; 为了解细胞周期蛋白E2（cyclin E2）和存活蛋白（survivin）在急性白血病中基因表达及两者间的相关性，采用逆转录－聚合酶链反应的方法检测了84例成人急性白血病患者（16例复发患者，60例初治患者和8例持续缓解患者）和20例正常人的cyclin E2 和survivin mRNA的表达。结果表明： ①cyclin E2在急性白血病中表达的阳性率（70.24％）高于对照组（0％）；survivin在急性白血病中表达的阳性率（72.62％）高于对照组（30％）；②在急性白血病中cyclin E2的表达与survivin的表达呈正相关性，r＝0.65；③cyclin E2阳性组缓解率（55.81％）低于cyclin E2阴性组（88.24％），cyclin E2阳性组复发率（41.67％）高于阴性组（20％）；复发组cyclin E2表达率在三组中最高，持续缓解组cyclin E2表达率在三组中最低，④cyclin E2在急性髓系白血病患者表达率（59.32％）低于急性淋巴细胞白血病患者的表达率（96％）；与发病时白细胞计数未见有统计学意义的相关。结论：首次证实cyclin E2在急性白血病中有异常表达，且对临床预后有不良影响；cyclin E2在急性白血病中的表达与survivin有正相关，提示cyclin E2在急性白血病中有可能作为一种微小残留病变的检测指标。 毕业论文 【关键词】; 存活蛋白 毕业论文 　　As a malignant hemophaty，acute leukemia (AL)，especially，acute lymphocytic leukemia （ALL）; underwent a high relapse rate and a short disease-free; survival (DFS)，in spite of the improvement in clinical outcome; benefited from the development of hematopoietic stem cell transplantation (HSCT) and chemical therapy.Preventing relapse and prolonging DFS still is; the focus of; AL; therapy.Minimal residual disease (MRD) became an effective indication; for the foundation of post-remission therapy regulation since the routine morphological examination of the peripheral blood and; bone marrow sample from the remission patient was normal.But the fusion gene such as AML1/MTG8 and PML/RARα as; MRD marker，was only used in M2，M3，so it is valuable to search another new MRD marker for leukemia.On the other hand，RNA interference (RNAi) as a new and prospective gene therapy; for cancer has become a new focus of the study of AL; therapy［1］.Searching for an effective new target for a tumor-specific RNAi; is worth developing for leukemia therapy.Recently，as a type of G1 cyclin，cyclin E2 was found out to be the potential marker of tumors since it presented a positive expression in the cell lines of solid tumors and a negative expression in proliferating normal cells［2］.However，there has been no report o